The biotech sector demonstrates signs of revival as Bay Area companies achieve remarkable milestones this summer. With $1.2 billion in initial public offerings and seven FDA drug approvals, the industry signals potential emergence from a prolonged five-year contraction. These developments suggest renewed investor confidence and accelerated therapeutic innovation. However, analysts question whether this momentum can be sustained beyond the current season, given market volatility and funding challenges that have plagued the sector.

Summary auto-generated by AI from the original publisher's content. Editorial standards.